Annual General Practitioner Study Day 2012 Men’s Health Workshop Managing side effects of male cancer therapy Dr Conleth Murphy, Consultant Medical Oncologist.

Slides:



Advertisements
Similar presentations
Prostate Cancer What a GP Needs to Know
Advertisements

Castrate-resistant prostate cancer (CRPC)
Medical Statistics Joan Morris Professor of Medical Statistics Goldsmiths Lecture 2014.
2009. WHO IS A SURVIVOR? AN INDIVIDUAL IS A SURVIVOR FROM THE TIME OF THEIR DIAGNOSIS THROUGH THE BALANCE OF THEIR LIFE.
Managing the Side Effects of Androgen Deprivation Therapy Celestia (Tia) Higano, MD, FACP Professor Departments of Medicine and Urology University of Washington.
Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.
Pharmacology in Nursing Men’s Health Drugs
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 35 Men’s Health Drugs.
Prostate Cancer: What’s New
PSA Screening and “Mojo” Maintenance in Prostate Cancer.
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed.
Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.
JANET P. PREGLER, MD; CAROLYN J. CRANDALL, MD, MS. ANNALS OF INTERNAL MEDICINE. 2011; 155: JULIANNA L. MURPHY PHARM.D. CANDIDATE PRECEPTOR: ALI RAHIMI,
“Fighting Cancer: It’s All We Do.” ™. Restoring Quality of Life And Managing Side Effects Ulka Vaishampayan M.D. Chair, GU Multidisciplinary team Associate.
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
Diabetes and Kidney. Diabetic Kidney Normal Kidney.
MANAGING THE MENOPAUSE SUMMARY HRT appropriate for moderate to severe symptoms HRT appropriate for moderate to severe symptoms HRT should not be.
MENOPAUSE DR. AMEL EL-SAYED, FRCSC Assistant Professor & Consultant King Saud University King Khalid University Hospital.
How to survive your menopause David Griffiths Consultant Gynaecologist Christine Pearce Consultant Nurse 3 rd Sept 2014.
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD.
Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology
Symptoms & Sequelae of Chronic Androgen Deprivation Dr Charles Chabert.
The University of Wisconsin Medical School The Center for Tobacco Research and Intervention Treating Tobacco Addiction in a Subject concerned about Weight.
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
New developments in Prostate Cancer Dr Jo Bowen Consultant Oncologist Worcestershire Royal Hospital.
Life after Prostate Cancer and its treatment Mr Sanjeev Pathak Consultant Urological Surgeon and Cancer Lead Doncaster and Bassetlaw NHS Trust 12 th March.
J Clin Oncol 31: © 2013 by American Society of Clinical Oncology GASTROENTEROLOGY 2012;143:897–912. Journal conference.
Featured Article: Wayne H.-H. Sheu, Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Arpana Mirza, Barry J. Goldstein, Keith D. Kaufman, and Samuel S. Engel.
Casodex 50mg - Prostate Cancer Drug Casodex 50 mg is a prostate cancer drug used in hormonal therapy to treat the same. It reduces production of androgen.
1 RTOG 1115 Health Related Quality of Life and Comparative Effectiveness Deborah Watkins Bruner, RN, PhD, FAAN.
Graph paper template R2 이지훈 / Prof. 맹치훈 Lancet Oncol 2012; 13:
Matthew Raymond Smith, MD, PhD Professor of Medicine Harvard Medical School Program Director, Genitourinary Oncology Massachusetts General Hospital Cancer.
Bones, Hot Flashes, and ADT Use With Chemotherapy and Timing
Introduction and Current ADT Challenges
Other Side Effects: Perception vs. Evidence
Abiraterone Changes in Landscape of Advanced Prostate Cancer
Management of Diabetes in the Older Person
Prednisone for MG Richard J. Barohn, MD Gary Gronseth, MD
Recurrent falls in an older woman with diabetes
New developments in Prostate Cancer
Patient Information Sheet
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Updates in Prostate Cancer Prepared for GP master class – Sept 2016
Improving Quality of Life (QoL) in Hormonal Therapy (ADT)
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand  Bannakij Lojanapiwat, Choosak Pripatnanont,
CONVERSATIONS ON PROSTATE CANCER
Systemic treatment for metastatic prostate cancer
Management of Diabetes in the Older Person
SYSTEMIC THERAPY OF PROSTATE CANCER
Bergh J et al. SABCS 2009;Abstract 23.
Prostate Cancer Management: What Does the Future Hold?
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements 
Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care  Fred Saad, Carl Olsson, Claude C. Schulman 
Deciding on Pharmacological Treatment Post Fracture
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Deciding on Pharmacological Treatment Post Fracture
Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Jacques Irani  European Urology Supplements 
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES
Improving Flexibility and Quality of Life for Your Patients: A Must?
Bob Djavan  European Urology Supplements 
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
Manfred Wirth, Peter Iversen, David McLeod, William See 
Maintaining bone health while on ADT for Prostate Cancer
Presentation transcript:

Annual General Practitioner Study Day 2012 Men’s Health Workshop Managing side effects of male cancer therapy Dr Conleth Murphy, Consultant Medical Oncologist

Prostate cancer therapies Endocrine therapies – ADT: Orchiectomy or LHRH analogues – Anti-androgens: bicalutamide (casodex) Chemotherapy – Docetaxel (Taxotere) – Cabazitaxel Novel therapies – Abiraterone (Zytiga)

Androgen Deprivation Therapy Cognitive dysfunction Worsening of diabetes Hot flashes Weight gain Erectile dysfunction Cardiovascular effects Loss of libido Osteoporosis Anaemia Sarcopaenia

Side effects of ADT Hot flashes – Acupuncture 1, venlafaxine 2, medroxyprogesterone acetate 2 (20mg/day), cyproterone 2 (androcur), gabapentin. Anaemia – Monitor B12, folate, TIBC. Avoid EPO Metabolic syndrome and cardiovascular health – 50% of men on long term ADT have metabolic syndrome. – Monitor BP, lipids and glucose. – Encourage diet and resistance exercise. – Cardiology review for men with pre-existing IHD 1.Frisk J, Spetz AC, Hjertberg H, Petersson B, Hammar M. Two modes of acupuncture as a treatment for hot flashes in men with prostate cancer—a prospective multicenter study with long-term follow-up. European Urology. 2009;55(1):156–163 2.Irani J, Salomon L, Oba R et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial, The Lancet Oncology, Volume 11, Issue 2, February 2010, Pages

Osteoporosis Osteoporosis is common – ~35% of hormone-naïve men with prostate CA – ~80% after 10 years of ADT Baseline DEXA Repeat at least every 2 years Weight bearing and resistance exercise Calcium 1200mg + Vit D 800 u daily Zoledronic acid 4mg IV yearly Alendronate 70mg weekly orally Denosumab 60mg S/C q6/12 reduced fracture risk.

Chemotherapy Up to 10 cycles of docetaxel – Febrile neutropaenia: reduced with neulasta – Nail changes: cold gloves can help – Neuropathy: dose reduction, pregabalin – Watery eyes: lubricants, steroid eyedrops, intervention for canal stenosis – Anaemia: correct deficiencies, consider EPO Steroids reduce fluid retention Please call with any concerns Continue LHRH analogue throughout Rx Cabazitaxel: similar but high rates diarrhoea and neutropaenia

Abiraterone Novel oral inhibitor of androgen synthesis – Improves survival c/w best supportive care – 4x 250mg tablets daily 2 hrs after food – Prednisolone 10mg daily Oedema Hypertension Abnormal LFTs Hypokalaemia – Check BP, LFTs, U&E every 2 weeks for 3 months